Fraunhofer ITEM: News

 

News / 11.6.2025

Linda Steinacher receives MHH doctoral prize

Award for outstanding doctoral thesis about immune organoids.

Press release / 5.5.2025

Miniature Hearts: Cardiac Organoids With an Immune System

Multicellular human cardiac organoids for drug research.

Press Release / Research News / 1.8.2024

Toxicological assessment of e-liquids

Project EVape helps improve consumer safety in the e-cigarette segment.

 

News / 16.5.2025

How do metastases form?

This is the question the research teams addressed in their publication in Nature Cancer.

 

Press release / 5.5.2025

Expert interview on synthetic biology

Synthetic DNA as Mass Data Storage of the Future.

 

News / 3.12.2024

Inhale+

Fraunhofer ITEMs spin-off project receives a boost of €1.3 million. The technology aims to revolutionize inhalation therapy for premature babies.

Press release / 16.4.2024

Miniature Lab

New opportunity for cancer therapy: Miniature Lab provides insights into metastases development.

Our research and development expertise

For more than four decades, we have been developing solutions for human health

 

Lung research

Research for healthy lungs: Airway research has been a focus at Fraunhofer ITEM ever since the institute was founded. 

Medical and pharmaceutical engineering

Next to innovative inhalation technologies, our focus is on developing novel technologies for administration of therapeutic aerosols by means of smart drug/device combination products.

 

Malignant disease research

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Bioinformatics and AI

Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.

 

RNA technologies

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.

 

Toxicology

Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.

 

Immunology and infection research

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.

Our services

 

Translational Biomedical Engineering

From idea to safe medical device:

 

 

Personalized Tumor Therapy

From molecular analysis to personalized therapy:

 

Meet Fraunhofer ITEM at fairs and congresses

Events

20.11.2025

Alternatives to Animal Testing 2025

We invite you to join us for our workshop, where we will explore and discuss cutting-edge model systems, the development of enabling technologies, and the implementation of alternative testing strategies.
more info

10.9.2025

Fraunhofer CIMD Symposium RNA-Based Therapeutics

RNA-research in the focus - at the Fraunhofer CIMD Symposium RNA-Based Therapeutics at Fraunhofer ITEM in Hannover on September 10 and 11, 2025. Read more here.
more info

2.7.2025

JSOT 2025

Dr. Gustav Bruer will give a presentation at the JSOT Congress in Okinawa, Japan, the 52nd Annual Meeting of the Japanese Society of Toxicology, in the category “Respiratory system”.
more info

19.6.2025

Models of Lung Disease 2025

June 19 and 20 - our conference "Models of Lung Disease" for experts in lung research. Please save the date for the 23rd Fraunhofer Seminar "Models of Lung Disease". Join us! We would be pleased to welcoming you there.
more info

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 76 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on lung research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of around 450 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.

 

More information about Fraunhofer ITEM